

Resource Summary Report

Generated by ASWG on Aug 10, 2026

PE anti-mouse CD4

RRID:AB_312693

Type: Antibody

Proper Citation

BioLegend Cat# 100408, RRID:AB_312693

Antibody Information

URL: http://antibodyregistry.org/AB_312693

Proper Citation: BioLegend Cat# 100408, RRID:AB_312693

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone GK1.5

Antibody ID: AB_312693

Vendor: BioLegend

Catalog Number: 100408

Alternative Catalog Numbers: 100407

Record Creation Time: 20250820T003927+0000

Record Last Update: 20250820T085113+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-mouse CD4.

No alerts have been found for PE anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 90 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Zhang Y, et al. (2026) Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice. *Cell host & microbe*, 34(2), 212.

Chava S, et al. (2026) Loss of EHMT2 enhances NK cell-driven anti-tumor immunity through TGF- β 1 suppression. *EMBO molecular medicine*, 18(1), 232.

Zhang X, et al. (2026) Tumor Cell-Derived Microparticles Induced by Methotrexate Reprogram Neutrophil Antitumor Response via Lysosomal ROS-Mediated Degranulation. *Molecular cancer research : MCR*, 24(4), 293.

Yu X, et al. (2026) Bacterial vesicles from intratumoral *L. salivarius* enhance PD-1 blockade via FPR1-mediated macrophage polarization in gastric cancer. *Cell reports. Medicine*, 7(2), 102621.

Yao B, et al. (2026) Divergent tumor immunity determined by bacteria-cancer cell engagement. *Cell*, 189(6), 1748.

Yan X, et al. (2026) Activation of T Cell-Intrinsic p53 by Acetylation Elicits Antitumor Immunity to Boost Cancer Immunotherapy. *Cancer discovery*, 16(1), 155.

Heaton AR, et al. (2026) Divergent role of CD8 T cells with distinct metabolic phenotypes during curative radio-immunotherapy in hot versus cold tumors. *bioRxiv : the preprint server for biology*.

Izawa K, et al. (2026) IgE-dependent anaphylaxis is regulated by sphingolipid binding to activating and inhibitory CD300 family members. *Cell reports*, 45(3), 117054.

Feng F, et al. (2026) Synthetic M13 phage engagers expand CAR-T cell antigen recognition to overcome tumor heterogeneity. *Trends in biotechnology*, 44(7), 1987.

Yang N, et al. (2026) Pan-cancer macrophage atlas uncovers that MHC-II^{high} TAMs induce Treg activation through physical interactions. *Cell reports*, 45(4), 117230.

Shao LJ, et al. (2026) Myeloid MMP14 couples extracellular proteolysis to inflammatory and metabolic remodeling during obesity. *Cell reports*, 45(7), 117681.

Tang R, et al. (2026) Neoantigens and shared MICB ?3 antigen dual-targeted vaccine generates potent antitumor immunity. *EMBO molecular medicine*, 18(6), 2098.

Horvath D, et al. (2026) PLGA-particle-based vaccine induces SARS-CoV-2-specific antibody and T-cell responses. *British journal of pharmacology*, 183(13), 3619.

Feng C, et al. (2026) METTL3/CD98-mediated glutamate efflux in CAFs drives CD8+ T cell exhaustion and impedes neoadjuvant immunochemotherapy. *Cell reports*, 45(2), 116933.

Peng M, et al. (2026) MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells. *Cell stem cell*, 33(5), 800.

Zhang P, et al. (2026) Sympathetic-epithelial crosstalk governs tissue-resident memory T cell immunosurveillance in the skin. *Cell*, 189(5), 1323.

Deng T, et al. (2025) CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. *Immunity*, 58(9), 2336.

Wu J, et al. (2025) Vitamin B6 preserves the stemness-like phenotypes and antitumor ability of CD8+ T cells. *Developmental cell*.

Arnouk SM, et al. (2025) Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti-PD-1 Immunotherapy. *Cancer research*, 85(23), 4681.

Neuwirth T, et al. (2025) The polyamine-regulating enzyme SSAT1 impairs tissue regulatory T cell function in chronic cutaneous inflammation. *Immunity*, 58(3), 632.